RecruitingAccepts healthy volunteers

Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)

University of Texas Southwestern Medical Center · with National Heart, Lung, and Blood Institute (NHLBI) · NCT06292104

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Status re-checked against ClinicalTrials.gov within the last 12 hours.

This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities.

Being studied: multimodal diagnostic testing

Conditions: Postural Orthostatic Tachycardia Syndrome

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

POTS Patients

Age ≥ 14 years, able to provide informed consent (assent with parental consent for age \< 18) and comply with procedures
Meets consensus criteria for POTS: (1) sustained increase in heart rate ≥ 30 bpm above supine baseline within 10 min of quiet standing or upright tilt (≥ 40 bpm in individuals 12 to 19 years of age) OR sustained upright HR (heart rate) >120 bpm, (2) absence of orthostatic hypotension, (3) symptoms with standing that improve with sitting or lying down, (4) resting supine heart rate \< 100 bpm, (5) orthostatic symptoms present for at least 6 months
Stable oral medication regimen for at least 14 days

Non-POTS Control Patients

Healthy women, age 18 - 30 years, able to provide informed consent and comply with study procedures
Does NOT meet consensus criteria for postural tachycardia syndrome
No symptoms of orthostatic intolerance or dysautonomia. No history of other major medical disorder
Resting supine heart rate \< 100 bpm

Exclusion Criteria

None of the following exclusion criteria

Use of amphetamine-type stimulants, diuretics, selective norepinephrine reuptake inhibitor, anticholinergic medications (including tricyclic antidepressant medications), fludrocortisone, desmopressin in past 14 days
Use of other autonomic drugs (adrenergic agents, pyridostigmine, droxidopa, triptans, ivabradine) in past 48 hours
Currently receiving IVIG (Intravenous immunoglobulin), subcutaneous IgG (Immunoglobulin G), or any investigational medication (in past year)
Infusion of iv fluids in past 7 days
History or evidence of another condition explaining symptoms or orthostatic tachycardia (e.g. structural heart disease, CSF (Cerebrospinal fluid) hypovolemia, or severe traumatic brain injury)

UT Southwestern Medical Center
Dallas, TX 75208
Site contact: Steven Hopkins · 2146489275 · steve.hopkins@utsouthwestern.edu